CN118931804B - Bifidobacterium longum subspecies and its progeny and application for reducing blood pressure and blood fat - Google Patents
Bifidobacterium longum subspecies and its progeny and application for reducing blood pressure and blood fat Download PDFInfo
- Publication number
- CN118931804B CN118931804B CN202411411734.9A CN202411411734A CN118931804B CN 118931804 B CN118931804 B CN 118931804B CN 202411411734 A CN202411411734 A CN 202411411734A CN 118931804 B CN118931804 B CN 118931804B
- Authority
- CN
- China
- Prior art keywords
- longum
- extract
- bifidobacterium longum
- blood pressure
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 claims description 57
- 239000008280 blood Substances 0.000 claims description 57
- 239000000284 extract Substances 0.000 claims description 56
- 230000036772 blood pressure Effects 0.000 claims description 51
- 241001608472 Bifidobacterium longum Species 0.000 claims description 42
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 42
- 238000000855 fermentation Methods 0.000 claims description 37
- 230000004151 fermentation Effects 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 37
- 150000002632 lipids Chemical class 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 20
- 235000013557 nattō Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 240000000249 Morus alba Species 0.000 claims description 15
- 235000008708 Morus alba Nutrition 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 14
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 claims description 13
- 244000068988 Glycine max Species 0.000 claims description 11
- 235000010469 Glycine max Nutrition 0.000 claims description 11
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000001888 Peptone Substances 0.000 claims description 8
- 108010080698 Peptones Proteins 0.000 claims description 8
- 235000019319 peptone Nutrition 0.000 claims description 8
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 claims description 6
- 244000253911 Saccharomyces fragilis Species 0.000 claims description 6
- 235000018368 Saccharomyces fragilis Nutrition 0.000 claims description 6
- 229940031154 kluyveromyces marxianus Drugs 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 235000013878 L-cysteine Nutrition 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 5
- 235000007688 Lycopersicon esculentum Nutrition 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 229940040511 liver extract Drugs 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000012138 yeast extract Substances 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 244000046101 Sophora japonica Species 0.000 claims 4
- 235000010586 Sophora japonica Nutrition 0.000 claims 4
- 240000003768 Solanum lycopersicum Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 36
- 230000001603 reducing effect Effects 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000628997 Flos Species 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 description 8
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000186000 Bifidobacterium Species 0.000 description 7
- 206010054949 Metaplasia Diseases 0.000 description 7
- 230000015689 metaplastic ossification Effects 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- -1 cholesterol Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000032928 Dyslipidaemia Diseases 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 241000227653 Lycopersicon Species 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000002960 lipid emulsion Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一株降血压、血脂的长双歧杆菌长亚种及其后生元和应用，涉及微生物发酵技术领域，本发明筛选得到一株长双歧杆菌长亚种（Bifidobacterium longumsubsp.longum）WZA‑BL01，其保藏编号为：CCTCC NO:M 20241531。通过发酵培养所述长双歧杆菌长亚种得到长双歧杆菌长亚种后生元，并将其与纳豆提取物、桑叶提取物组合制得降血压和血脂产品，所述产品可明显降低大鼠的尾静脉压和总胆固醇、甘油三酯、低密度脂蛋白的含量，提高高密度脂蛋白的含量，由此可见，本发明筛选得到的长双歧杆菌长亚种及其后生元可兼具降血压和降血脂双重功效。The present invention discloses a strain of Bifidobacterium longum subsp. longum and its postbiotics and applications for lowering blood pressure and blood lipids, and relates to the field of microbial fermentation technology. The present invention screens and obtains a strain of Bifidobacterium longum subsp. longum WZA-BL01, and its deposit number is: CCTCC NO: M 20241531. The Bifidobacterium longum subsp. longum postbiotics are obtained by fermenting and culturing the Bifidobacterium longum subsp. longum, and the postbiotics are combined with natto extract and mulberry leaf extract to prepare a blood pressure and blood lipid lowering product. The product can significantly reduce the tail vein pressure and the content of total cholesterol, triglyceride, and low-density lipoprotein of rats, and increase the content of high-density lipoprotein. It can be seen that the Bifidobacterium longum subsp. longum and its postbiotics obtained by the present invention can have the dual effects of lowering blood pressure and lowering blood lipids.
Description
Technical Field
The invention relates to the technical field of microbial fermentation, in particular to a bifidobacterium longum subspecies longum for reducing blood pressure and blood fat and a metaplasia and application thereof.
Background
Modern physiology considers that blood pressure is the lateral pressure of blood acting on the wall of a unit area when flowing in a blood vessel, and is the dynamic force for pushing the blood to flow in the blood vessel, while hypertension is the continuous exceeding of normal value, so that the wall of the blood vessel is subjected to higher than normal pressure for a long time, and the blood vessel is subjected to brittle injury, thereby damaging the functions of organs such as heart, brain, kidney and the like. The blood fat is taken as basic metabolic essential substances of life cells, and comprises neutral fat such as triglyceride and lipid such as cholesterol, and the hyperlipidemia (dyslipidemia) refers to that cholesterol or triglyceride in blood plasma exceeds a normal value for a long time, so that the blood fat is deposited on a blood vessel wall, and the blood vessel is blocked, thereby inducing diseases of organs such as brain, kidney, eyes and the like. Hyperlipidemia and hypertension are chronic diseases, and the hyperlipidemia and hypertension are usually induced by each other, i.e. hypertension can cause hyperlipidemia, and hyperlipidemia can also cause hypertension. Therefore, the treatment of the hypertension and the dyslipidemia must be treated by an omnibearing control concept, and the blood pressure and the dyslipidemia cannot be reduced simply.
The metazoan is the metabolite component of the probiotics after the probiotics are processed and treated. Because the medicine does not contain living bacteria, the medicine has high biological safety, and meanwhile, the medicine has small molecules, can quickly enter the body through intestinal mucosa, and has direct and quick functionality. Many evidences suggest that the metazoan may be beneficial for management of metabolic diseases by potential effects, where hypertension and dyslipidemia are typical metabolic diseases.
Bifidobacterium longum is widely existing in intestinal tracts of human beings and animals, is a strain recorded in a strain list applicable to food and a strain list applicable to infant foods in China, and comprises Bifidobacterium longum subspecies (Bifidobacterium longum subsp. Longum), bifidobacterium longum subsp. Infantis (Bifidobacterium longum subsp. Infantis) and the like. In the prior art, CN181146998A discloses a bifidobacterium longum subspecies KS1 and application thereof in preparing anti-aging and sleep-aiding food and medicine, wherein the bifidobacterium longum subspecies KS1 can be used as renin inhibitor for further preventing and treating hypertension, but cannot play a role in reducing blood fat, and CN116814501B discloses a bifidobacterium subspecies longum subspecies for relieving obesity and application thereof, which can only reduce blood fat level and cannot reduce blood pressure.
Therefore, it is necessary to screen a bifidobacterium longum subspecies (Bifidobacterium longum subsp. Longum) and use it to prepare corresponding metazoans to achieve dual effects of lowering blood pressure and lowering blood lipid.
Disclosure of Invention
Aiming at the prior art, the invention aims to provide a bifidobacterium longum subspecies longum strain for reducing blood pressure and blood fat and a metaplasia and application thereof.
In order to achieve the above purpose, the invention adopts the following technical scheme:
In a first aspect of the invention, a bifidobacterium longum subspecies (Bifidobacterium longum subsp. Longum) WZA-BL01 for reducing blood pressure and blood fat is provided, and the strain is preserved in China center for type culture collection (CCTCC for short, eight-path 299-No. Wuhan university in Wuchang district of Wuhan, hubei province) at 7 months and 10 days in 2024, and the preservation number is CCTCC NO: M20241531.
In a second aspect of the invention, there is provided a bifidobacterium longum subspecies longum metazoan prepared by the method of:
(1) Inoculating long bifidobacterium subspecies into a fermentation medium for fermentation to obtain fermentation liquor;
(2) Centrifuging the fermentation liquor, taking supernatant, and drying to obtain the bifidobacterium longum subspecies longum metazoan.
Preferably, in the step (1), the fermentation medium comprises 10-20g/L of peptone, 15-25g/L of glucose, 1.5-2.5g/L of yeast extract powder, 0.3-0.6g/L of soluble starch, 3-6g/L, L-cysteine 0.3-0.6g/L of sodium chloride, 3-6g/L of tomato extract powder, 1.5-2.5g/L of liver extract powder, 0.5-1.5mL/L of tween-80, 30-50mg/L of pagodatree flower bud extract and pH of 7.0+/-0.1 (25 ℃).
Further preferably, the flos Sophorae Immaturus extract is prepared by mixing flos Sophorae Immaturus and water (80-100 g:500 mL) at a ratio, decocting for 2-3 times, mixing decoctions, and drying to obtain flos Sophorae Immaturus extract.
Further preferably, the time of the decoction is 2-3 hours.
Preferably, in the step (1), the fermentation temperature is 35-40 ℃ and the fermentation time is 48-72h.
Preferably, in step (1), the inoculum size of the bifidobacterium longum subspecies longum is 10-20% of the volume of the fermentation medium.
In a third aspect of the invention, there is provided the use of bifidobacterium longum subspecies longum or a metazoan of bifidobacterium subspecies longum for the preparation of a blood pressure and blood lipid lowering product.
Preferably, the blood pressure and blood fat reducing product is prepared from longsubspecies longipes metaplasia, natto extract and mulberry leaf extract according to a ratio of 1:1:1.
Preferably, the mulberry leaf extract is prepared by mixing mulberry leaf and water in a mass ratio of 1:20, heating and refluxing for leaching for 3 times, mixing the leaching liquids, filtering and drying to obtain the mulberry leaf extract.
Preferably, the preparation method of the natto extract comprises the steps of mixing bacillus subtilis seed liquid and Kluyveromyces marxianus seed liquid according to a ratio of 1:1 to obtain mixed seed liquid, inoculating the mixed seed liquid into a soybean culture medium, fermenting for 48 hours at 37 ℃ to obtain fermentation liquor, centrifuging the fermentation liquor, taking supernatant and drying to obtain the natto extract.
More preferably, the inoculation amount of the mixed seed liquid is 10% of the volume of the soybean culture medium.
Further preferably, the strain of bacillus subtilis is ACCC 19373 and the strain of Kluyveromyces marxianus is ACCC 21190.
Further preferably, the soybean culture medium comprises 80g/L of soybean powder, 20g/L of peptone and 10g/L of sucrose.
The invention has the beneficial effects that:
The invention obtains bifidobacterium longum subspecies (Bifidobacterium longum subsp. Longum) WZA-BL01 with acid resistance and cholate resistance through screening, obtains bifidobacterium subspecies metazoan through fermentation culture of the bifidobacterium subspecies, and compounds the subspecies with natto extract and mulberry leaf extract to obtain a composition, namely the blood pressure and blood fat reducing product. The product can obviously reduce the tail vein pressure (systolic pressure) of the SHR rat, can obviously reduce the content of total cholesterol, triglyceride and the like in serum of the rat and increase the content of high-density lipoprotein, so that the product prepared by the invention can simultaneously have the effects of reducing blood pressure and blood fat. From the experimental data, it can be seen that the long subspecies metaplasia of bifidobacterium longum, the natto extract and the mulberry leaf extract have a synergistic effect in reducing blood pressure and blood fat. In addition, the pagodatree flower bud extract is added into the fermentation medium, so that the blood pressure and blood fat reducing effect of the long subspecies of bifidobacterium longum can be improved, and the efficacy of blood pressure and blood fat reducing products can be further improved.
Detailed Description
It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the application. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
In order to enable those skilled in the art to more clearly understand the technical scheme of the present application, the technical scheme of the present application will be described in detail with reference to specific embodiments.
The test materials used in the examples of the present invention are all conventional in the art and are commercially available.
The SPF-class male SHR rats are purchased from Beijing-Venetthrough Lihua experimental animal technology Co., ltd, the SPF-class male SD rats and the basal feed are purchased from Jinan Pengyue experimental animal breeding Co., ltd, and the bacillus subtilis and the Kluyveromyces marxianus are purchased from China center for type culture collection of agricultural microorganisms, and the strain numbers are ACCC 19373 and ACCC 21190 respectively.
Example 1 isolation and identification of strains
1. Isolation and preliminary screening of strains
10G of healthy adult feces samples were collected, the feces samples were subjected to 10-fold gradient dilution with PBS dilution, 100. Mu.L of each of the dilutions 10 -4、10-5、10-6 and 10 -7 were coated on a modified MRS solid medium, anaerobic culture was performed at 37℃for 48 hours, and colony morphology was recorded.
Selecting bacterial colony with round bulge, smoothness and neat edge, carrying out streak purification on opaque milky single bacterial colony, inoculating the bacterial colony into an MRS liquid culture medium for anaerobic culture, then carrying out gram staining on the bacterial colony, selecting bacterial strain with gram positive and catalase negative, carrying out streak purification on the MRS culture medium for more than 3 times, selecting bacterial colony with larger bacterial colony and stronger reproductive capacity, numbering, and then inoculating the bacterial colony into an MRS solid flat plate for streak purification culture.
2. Screening of strains for acid and bile salt resistance
Activating the strain, inoculating the strain into an MRS culture medium, performing anaerobic culture at 37 ℃ for 24 hours, centrifuging, and re-suspending the centrifuged precipitate with PBS to obtain bacterial suspension;
Bacterial suspensions were inoculated into MRS media at pH 2.0, 3.0, 4.0, 5.0 and 6.0 and MRS media at bile salt concentrations (w/v) of 0.1%, 0.2%, 0.3%, 0.4% and 0.5%, respectively, and the survival rate was calculated by counting viable bacteria using MRS media at pH 7.0 and MRS media without bile salt as blank control groups. And selecting the strain with higher survival rate for subsequent identification.
3. Identification of strains
The WZA-BL01 strain is sent to the Henan industrial microorganism strain engineering technology research center for 16S rDNA gene sequence identification, and the 16S rDNA gene sequence is shown as SEQ ID NO. 1.
The identification result shows that the strain belongs to Bifidobacterium longum subsp.longum, and the strain is subjected to biological preservation, and the preservation information is as follows:
The strain name is Bifidobacterium longum subspecies longum WZA-BL01
Latin name Bifidobacterium longumsubsp.longum
China center for type culture Collection
CCTCC for preservation organization
Address of Wuhan university in Wuchang district, wuhan, hubei province, eight-way No. 299
The preservation date is 2024, 7 and 10
The preservation number is CCTCC No. M20241531.
Example 2 preparation of Long subspecies metazoan of Bifidobacterium longum
(1) Activating long subspecies of bifidobacterium longum, inoculating the activated long subspecies of bifidobacterium longum into a fermentation culture medium according to the volume ratio, and fermenting for 48 hours at 37 ℃ to obtain fermentation liquor;
The fermentation medium comprises 15g/L of peptone, 20g/L of glucose, 2.0g/L of yeast extract powder, 0.5g/L of soluble starch, 5.0g/L, L-cysteine 0.5g/L of sodium chloride, 5.0g/L of tomato extract powder, 2.0g/L of liver extract powder, 1.0ml/L of tween-80, 40mg/L of pagodatree flower bud extract, and pH of 7.0 (25 ℃);
the flos Sophorae Immaturus extract is prepared by mixing flos Sophorae Immaturus and water at a ratio of 90g to 500mL, decocting for 3 times, each time for 3 hr, mixing decoctions, and drying to obtain flos Sophorae Immaturus extract;
(2) Centrifuging the fermentation liquor, taking supernatant, and freeze-drying to obtain the long subspecies metaplasia of the bifidobacterium longum;
And collecting the centrifuged thallus sediment, adjusting the viable count of the thallus sediment to 2X 10 9 cfu/g, and storing the thallus sediment in a refrigerator at 4 ℃ for standby.
Example 3 preparation of Long subspecies metazoan of Bifidobacterium longum
(1) Activating the bifidobacterium longum subspecies preserved in the example 1, inoculating the activated bifidobacterium subspecies into a fermentation medium according to the volume ratio of 10%, and fermenting for 72 hours at the temperature of 35 ℃ to obtain a fermentation liquid;
The fermentation medium comprises 10g/L of peptone, 15g/L of glucose, 1.5g/L of yeast extract powder, 0.3g/L of soluble starch, 3.0g/L, L-cysteine 0.3g/L of sodium chloride, 3.0g/L of tomato extract powder, 1.5g/L of liver extract powder, 0.5ml/L of tween-80, 30mg/L of pagodatree flower bud extract, and pH of 7.0 (25 ℃);
The flos Sophorae Immaturus extract is prepared by mixing flos Sophorae Immaturus and water at a ratio of 80g to 500mL, decocting for 2 times, each time for 2.5 hr, mixing decoctions, and drying to obtain flos Sophorae Immaturus extract;
(2) Centrifuging the fermentation liquor, taking supernatant, and freeze-drying to obtain the bifidobacterium longum subspecies longum metazoan.
Example 3 preparation of Long subspecies metazoan of Bifidobacterium longum
(1) Activating the bifidobacterium longum subspecies preserved in the example 1, inoculating the activated bifidobacterium subspecies into a fermentation medium according to the volume ratio of 20%, and fermenting for 48 hours at 40 ℃ to obtain a fermentation liquid;
the fermentation medium comprises 20g/L of peptone, 25g/L of glucose, 2.5g/L of yeast extract powder, 0.6g/L of soluble starch, 6.0g/L, L-cysteine 0.6g/L of sodium chloride, 6.0g/L of tomato extract powder, 2.5g/L of liver extract powder, 1.5ml/L of tween-80, 50mg/L of pagodatree flower bud extract, and pH of 7.0 (25 ℃);
The flos Sophorae Immaturus extract is prepared by mixing flos Sophorae Immaturus and water at a ratio of 100g to 500mL, decocting for 2 times, each time for 2.5 hr, mixing decoctions, and drying to obtain flos Sophorae Immaturus extract;
(2) Centrifuging the fermentation liquor, taking supernatant, and freeze-drying to obtain the bifidobacterium longum subspecies longum metazoan.
Example 4 preparation of blood pressure and blood lipid lowering products
Mixing the metaplasia longifolia of Bifidobacterium longum, natto extract and folium Mori extract obtained in example 2 at a ratio of 1:1:1 to obtain blood pressure and blood lipid lowering product.
The preparation method of folium Mori extract comprises mixing folium Mori and water at a mass ratio of 1:20, heating and reflux extracting for 3 times, mixing the extractive liquids, filtering, and lyophilizing to obtain folium Mori extract;
The preparation method of the natto extract comprises the steps of mixing bacillus subtilis seed liquid and Kluyveromyces marxianus seed liquid according to a ratio of 1:1 to obtain mixed seed liquid, adjusting the number of living bacteria of bacillus subtilis and Kluyveromyces marxianus in the mixed seed liquid to be 1X 10 8 cfu/mL, inoculating the mixed seed liquid into a soybean culture medium according to a volume ratio of 10%, fermenting for 48 hours at 37 ℃ to obtain fermentation liquid, centrifuging the fermentation liquid, taking supernatant and drying to obtain the natto extract, wherein the soybean culture medium comprises 80g/L of soybean powder, 20g/L of peptone and 10g/L of sucrose.
Comparative example 1 preparation of blood pressure and blood lipid lowering products
The blood pressure and blood lipid lowering product of this comparative example consisted of only the long subspecies of bifidobacterium longum metazoatum prepared in example 2.
Comparative example 2:
The blood pressure and blood lipid lowering product of this comparative example consisted of only natto extract.
Comparative example 3:
The blood pressure and blood lipid lowering products of this comparative example consisted of only mulberry leaf extract.
Comparative example 4:
the difference between this comparative example and example 4 is that the fermentation medium does not contain the pagodatree flower bud extract during the preparation of the long subspecies metazoan of bifidobacterium longum.
Experimental example 1 animal experiment for examining antihypertensive Effect
Animal experiments were conducted with reference to journal "study of hypotensive mechanism of spontaneous hypertensive rats with wolfberry proteolysis solution (Tao Yao et al, food industry science and technology vol.40, no.10,2019)". The method comprises the following specific steps:
SPF healthy male 12-week-old primary hypertension rats (SHR) with weight of 250-300g are selected, the material basic feed is suitable for 7 days of feeding, the feeding temperature is 25+/-2 ℃, the humidity is 50-60%, and 12 hours of light and shade alternate illumination is carried out, and water and food are freely drunk.
SHR rats were randomly divided into 7 groups of 10 animals each, blank and treatment groups 1-5, each group being specifically treated as follows:
blank group, namely, gastric lavage distilled water;
Probiotic group bacterial precipitation of bifidobacterium longum subspecies longum prepared in gastric lavage example 2;
Treatment group 1 blood pressure and blood lipid lowering product solution prepared in stomach lavage example 4;
Treatment group 2 blood pressure and blood lipid lowering product solution prepared in comparative example 1 by gastric lavage
Treatment group 3 blood pressure and blood lipid lowering product solution prepared in comparative example 2;
Treatment group 4 blood pressure and blood lipid lowering product solution prepared in comparative example 3;
treatment group 5 blood pressure and blood lipid lowering product solution prepared in comparative example 4 by gavage.
The blood pressure and blood lipid lowering product solutions used in treatment groups 1-5 were prepared by mixing blood pressure and blood lipid lowering products with water at a ratio of 0.001g:1 mL. The rats of each group are subjected to gastric lavage once a day in the morning, the gastric lavage amount of each time is 0.5mL (1 g of the probiotics group is regarded as 1 mL), the continuous gastric lavage is carried out for 5 weeks, and the nursing measures and the feeding management of the rats of each group are completely the same during the test period.
Each rat was trained for 30min in the morning with a non-invasive rat tail blood pressure monitor during the 1-3 week period prior to the test to adapt the animals to the blood pressure monitoring environment. The tail vein pressure (i.e., systolic blood pressure) of the rats was measured 1h a day on weeks 4-6 of the test run, and the results were averaged and shown in table 1.
Table 1 results of rat tail venous pressure test
The invention adopts the primary hypertension rat as the experimental object, and the products for reducing blood pressure and blood fat by filling the stomach are reflected by measuring the tail vein pressure (i.e. systolic pressure) of the rat. As can be seen from Table 1, since the rats in the blank group are not infused with the products for reducing blood pressure and blood fat, the tail vein pressure of the rats can reach 179.1mmHg, and the bacterial precipitation of the bifidobacterium longum subspecies prepared in example 2 can obviously reduce the tail vein pressure of the rats, so that the bifidobacterium longum subspecies screened by the invention have the effects of reducing blood pressure and blood fat.
Meanwhile, the blood pressure and blood fat reducing products prepared by the invention are used for lavaging, the tail vein pressure of the rat can be reduced to 126.5mmHg, and the metaplasia, the natto extract and the mulberry leaf extract are respectively used as blood pressure and blood fat reducing products for lavaging the SHR rat, and although the blood pressure reducing products can play a certain role, the tail vein pressure of the rat is still higher than 145.2mmHg. Therefore, the metazoan, the mulberry leaf extract and the natto extract prepared by adopting the bifidobacterium longum subspecies longum WZA-BL01 have a synergistic effect on reducing blood pressure. In addition, the invention can improve the blood pressure reducing effect of the metazoan prepared by the bifidobacterium longum subspecies WZA-BL01 by adding the pagodatree flower bud extract into the fermentation culture medium.
Test example 2 animal experiment for investigating hypolipidemic Effect
Rat animal experiments were performed with reference to the experimental method in chapter three of paper, "preparation of oat polypeptide and study of hypolipidemic and hypotensive effects of oat polypeptide" (university of Jiangsu, ma Chaoyue, 2018). The method comprises the following specific steps:
SPF-class SD rats with age of 6 weeks, weight of 120+ -20 g are selected, and are fed with basic feed for 7 days, the feeding temperature is 22+ -2deg.C, the humidity is 40-70%, and 12 hr alternately illuminate, and diet and water are fed freely.
10 Rats are randomly selected as a blank group, 1mL/100g (body weight) physiological saline is filled in each day, the rest rats are used as test groups, 1mL/100g (body weight) high-fat emulsion is filled in each day, 1 time is filled in each day, and the total period of time is 60 days, and meanwhile, each group of rats is guaranteed to normally supply drinking water and basic feed each day. The high-fat emulsion is prepared by mixing sucrose, lard, egg yolk, cholesterol, sodium cholate and basic feed according to the mass ratio of 10:12:10:1:0.5:66.5. After the last gastric lavage, rats in each group were fasted for 12h without water withdrawal, 1.5mL of blood was collected from the orbital venous plexus, and TG, TC, HDL-C and LDL-C were measured to reflect the blood lipid levels of the rats. When the blood lipid level of the rats in the experimental group is compared with that of the rats in the blank group, the significant difference appears, namely the modeling is successful.
SD rats successfully molded were selected and randomly divided into 7 groups of 10, respectively model group, treatment group 1-5 and positive control group, and the treatments for each group were as follows:
blank group, namely, gastric lavage distilled water;
probiotic group bifidobacterium longum subspecies longum bacterial sediment prepared in stomach filling example 2;
Treatment group 1 blood pressure and blood lipid lowering product solution prepared in stomach lavage example 4;
Treatment group 2 blood pressure and blood lipid lowering product solution prepared in comparative example 1 by gastric lavage
Treatment group 3 blood pressure and blood lipid lowering product solution prepared in comparative example 2;
Treatment group 4 blood pressure and blood lipid lowering product solution prepared in comparative example 3;
Treatment group 5 blood pressure and blood lipid lowering product solution prepared in comparative example 4;
The blood pressure and blood fat reducing product solution adopted by each treatment group is prepared by mixing blood pressure and blood fat products and water according to the ratio of 0.001g to 1mL, the stomach filling amount of each group of rats is 0.5mL (1 g of probiotics group is regarded as 1 mL) every morning, the stomach filling is carried out continuously for 30 days, and the high-fat emulsion is given to each group of rats during the test period, so that the nursing measures and the feeding management of each group of rats are completely the same.
After the last gastric lavage, rats in each group were fasted for 12 hours without water withdrawal, were anesthetized with 10% chloral hydrate at 400 mg/kg (body weight) and were subjected to abdominal anesthesia, the abdominal aorta was collected with 5 mL whole blood, left standing at room temperature, and after the blood was naturally coagulated, centrifuged (3500 rpm,10 min,4 ℃) to obtain the supernatant as serum, and total cholesterol TC, triglyceride TG, high-density lipoprotein HDL-C, low-density lipoprotein LDL-C in the serum were measured, and the results are shown in Table 2.
TABLE 2 blood lipid levels in serum of rats of each group
As can be seen from table 2, compared with the blank control group, the total cholesterol, triglyceride and low-density lipoprotein content of the probiotic group are obviously reduced, and the high-density lipoprotein content is obviously increased, so that the screened bifidobacterium longum subspecies have the efficacy of reducing blood pressure and blood fat.
Meanwhile, compared with a model group, the blood pressure and blood fat reducing product prepared by the invention can effectively reduce the content of total cholesterol, triglyceride and low-density lipoprotein in serum and improve the content of high-density lipoprotein, while comparative examples 1-3 respectively adopt metagen, natto extract and mulberry leaf extract as blood pressure and blood fat reducing products, the content of total cholesterol, triglyceride and low-density lipoprotein is still higher than the content of the product prepared in example 4 corresponding to the index in serum, and the content of high-density lipoprotein is lower than the content of the product prepared in example 4 corresponding to serum. Therefore, the metazoan, the mulberry leaf extract and the natto extract prepared by adopting the bifidobacterium longum subspecies WZA-BL01 have synergistic effect in reducing blood fat. In addition, the invention can improve the blood lipid reducing effect of the metazoan prepared by bifidobacterium longum subspecies WZA-BL01 by adding the pagodatree flower bud extract into the fermentation culture medium.
The above description is only of the preferred embodiments of the present application and is not intended to limit the present application, but various modifications and variations can be made to the present application by those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the protection scope of the present application.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411411734.9A CN118931804B (en) | 2024-10-11 | 2024-10-11 | Bifidobacterium longum subspecies and its progeny and application for reducing blood pressure and blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411411734.9A CN118931804B (en) | 2024-10-11 | 2024-10-11 | Bifidobacterium longum subspecies and its progeny and application for reducing blood pressure and blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118931804A CN118931804A (en) | 2024-11-12 |
| CN118931804B true CN118931804B (en) | 2025-02-07 |
Family
ID=93348908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411411734.9A Active CN118931804B (en) | 2024-10-11 | 2024-10-11 | Bifidobacterium longum subspecies and its progeny and application for reducing blood pressure and blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118931804B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927793A (en) * | 2017-11-28 | 2018-04-20 | 深圳爱米基因科技有限责任公司 | Prevention mitigates symphysis unit preparation of human body constipation and preparation method thereof |
| CN115944706A (en) * | 2022-12-06 | 2023-04-11 | 北京鹤之堂中医研究院有限公司 | Traditional Chinese medicine probiotic compound with blood sugar reducing function and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102224072B1 (en) * | 2019-08-19 | 2021-03-10 | 주식회사 빙그레 | Bifidobacterium longum subsp. longum having both abilities of reducing total cholesterol in serum and immune regulation and its application |
| CN116376740A (en) * | 2022-12-08 | 2023-07-04 | 杭州娃哈哈科技有限公司 | Bifidobacterium longum with blood sugar reducing effect and application thereof |
| CN118685300B (en) * | 2024-05-30 | 2025-02-18 | 迪辅乐生物(上海)有限公司 | Bifidobacterium longum subspecies longum and application thereof in preventing, relieving, regulating or treating lipid metabolism related diseases |
| CN118530915B (en) * | 2024-07-25 | 2024-10-18 | 山东健源生物科技有限公司 | Lactobacillus reuteri and its progeny capable of regulating gastrointestinal digestion |
-
2024
- 2024-10-11 CN CN202411411734.9A patent/CN118931804B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107927793A (en) * | 2017-11-28 | 2018-04-20 | 深圳爱米基因科技有限责任公司 | Prevention mitigates symphysis unit preparation of human body constipation and preparation method thereof |
| CN115944706A (en) * | 2022-12-06 | 2023-04-11 | 北京鹤之堂中医研究院有限公司 | Traditional Chinese medicine probiotic compound with blood sugar reducing function and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118931804A (en) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110604749B (en) | Bifidobacterium animalis A12 and its application in controlling diabetes or hyperlipidemia, especially weight gain or obesity | |
| CN107502575B (en) | A Lactobacillus plantarum with high α-glucosidase inhibitory activity | |
| CN114717146B (en) | Post-natal element prepared from lactobacillus paracasei and capable of relieving fatty liver and obesity and application of post-natal element | |
| CN114350577B (en) | Bifidobacterium animalis subsp lactis BLA36 for improving constipation and culture method and application thereof | |
| WO2013127148A1 (en) | Lactobacillus rhamnosus capable of relieving alcoholic chronic liver injury and application thereof | |
| CN114717147B (en) | Post-natal element prepared from lactobacillus rhamnosus and used for relieving fatty liver and obesity and application thereof | |
| CN113249280B (en) | A kind of Streptococcus thermophilus STN26, bacterial powder and application in uric acid lowering product | |
| CN113337428B (en) | Lactobacillus plantarum HNU082 and application thereof | |
| CN115381860B (en) | A composition for protecting alcoholic liver damage and its preparation method and application | |
| CN116254190A (en) | A kind of Lactobacillus paracasei subspecies and application thereof | |
| CN113755409A (en) | Bifidobacterium longum for relieving insulin resistance and application thereof | |
| CN116445356B (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| CN114848684A (en) | Composite probiotic composition with obvious effect of improving hyperlipidemia | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN118931804B (en) | Bifidobacterium longum subspecies and its progeny and application for reducing blood pressure and blood fat | |
| CN112029676B (en) | Probiotic composition beneficial to improving immunity and application thereof | |
| CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
| CN118440868A (en) | Lactobacillus plantarum and application thereof | |
| CN116286458B (en) | Lactobacillus plantarum LZ010 capable of reducing blood pressure and blood fat and application thereof | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| CN110839693A (en) | Application of Parabacteroides gibbsii in preventing or treating obesity or its related diseases | |
| CN105154362A (en) | Lactobacillus fermentum suo strain capable of preventing gastrohelcoma and health-care application thereof | |
| CN112391321B (en) | Bifidobacterium bifidum NX-7 and application thereof in preparation of medicines for treating ischemic diseases | |
| CN119351290B (en) | Animal-associated lactobacillus LA-1, microbial preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |